Although the role of CTLA‐4 upregulation in tumour cells remains unclear, the level of CTLA‐4 expression in melanoma cells has been associated with clinical response to the CTLA‐4 inhibitor ipilimumab, supporting its possible role as a predictive biomarker [47]. The gene discussed is CTLA4; the disease is neoplasm.